icon-    folder.gif   Conference Reports for NATAP  
 
  Back grey_arrow_rt.gif
 
 
 
 
 
Baseline NRTI resistance in suppressed participants did not lead to viral blips on bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) or dolutegravir (DTG)+F/TAF through week 48 in study 380-4030
 
 
  IAC2020 Virtual July 6-10
Rima Acosta, Gilead Sciences
 
Download the PDF here

0709201

0709202

0709203

0709204

0709205

0709206

0709207